Related Experiment Video

Updated: Oct 28, 2025

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

17.5K

P2X Receptors: Potential Therapeutic Targets for Symptoms Associated With Lung Cancer - A Mini Review

Yonglin Mai1, Zhihua Guo2, Weiqiang Yin2

  • 1Department of Allergy and Clinical Immunology, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

Frontiers in Oncology
|July 16, 2021
PubMed

Insights

Extracellular ATP and P2X receptors are implicated in lung cancer progression and symptoms. P2X receptor antagonists offer a promising, less-toxic alternative to opioids for managing cancer-related pain and other symptoms.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pain Management

Background:

  • Lung cancer symptoms like pain, cough, fatigue, and dyspnea significantly impact quality of life.
  • Current treatments for lung cancer symptom clusters are limited, necessitating novel therapeutic strategies.
  • Extracellular ATP and its P2 purinergic signaling pathway are increasingly recognized for their role in cancer development and symptoms.

Purpose of the Study:

  • To review the role of P2X receptors in lung cancer proliferation, progression, and metastasis.
  • To elucidate the involvement of P2 purinergic signaling in lung cancer-related symptoms.
  • To explore the potential of P2X receptor antagonists as anti-neoplastic and symptom-ameliorating agents.

Main Methods:

  • Literature review of recent findings on P2X receptors in oncology.
  • Analysis of P2 purinergic signaling mechanisms in tumor microenvironment.
  • Comparison of P2X receptor antagonists with traditional pain management like opioids.

Main Results:

  • P2X receptors on tumor cells, immune cells, and neurons modulate lung cancer development, invasion, and progression.
  • P2 purinergic signaling contributes to the pathogenesis of various lung cancer symptoms.
  • P2X receptor antagonists show potential for anti-neoplastic effects and symptom management.

Conclusions:

  • P2X receptors are critical players in lung cancer biology and symptom generation.
  • Targeting P2X receptors offers a novel therapeutic avenue for lung cancer.
  • P2X receptor antagonists may provide an effective and safer alternative to opioids for managing lung cancer symptom clusters.
Keywords:
ATPP2X receptorsantagonistcancer-related symptomstumor microenvironment

More Related Videos

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

9.2K
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

582

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
294
Pneumothorax-II01:27

Pneumothorax-II

Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
512
Other Pulmonary Disorders01:17

Other Pulmonary Disorders

Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
1.0K
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
3.5K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
294